Health Care & Life Sciences » Pharmaceuticals | Synthetic Biologics Inc.

Synthetic Biologics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
14,625.00
17,525.00
20,818.00
19,055.00
17,116.00
28,918
Total Accounts Receivable
-
-
-
185.00
46.00
-
Other Current Assets
1,591.00
1,548.00
9,519.00
2,330.00
781.00
593
Total Current Assets
16,216.00
19,073.00
30,337.00
21,570.00
17,943.00
29,511
Net Property, Plant & Equipment
37.00
65.00
494.00
905.00
872.00
607
Other Assets
4.00
6.00
14.00
23.00
23.00
23
Total Assets
16,257.00
19,144.00
30,845.00
22,498.00
18,838.00
30,141
Accounts Payable
142.00
996.00
4,413.00
1,993.00
2,020.00
Other Current Liabilities
885.00
8,592.00
11,162.00
17,764.00
7,773.00
Total Current Liabilities
1,027.00
9,588.00
15,575.00
19,757.00
9,793.00
Other Liabilities
-
-
267.00
492.00
402.00
Total Liabilities
1,027.00
9,588.00
15,842.00
20,249.00
10,195.00
Common Equity (Total)
15,230.00
9,556.00
16,051.00
3,845.00
1,496.00
Total Shareholders' Equity
15,230.00
9,556.00
16,051.00
3,845.00
10,557.00
Total Equity
15,230.00
9,556.00
15,003.00
2,249.00
8,643.00
Liabilities & Shareholders' Equity
16,257.00
19,144.00
30,845.00
22,498.00
18,838.00
Accumulated Minority Interest
-
-
1,048.00
1,596.00
1,914.00
Preferred Stock (Carrying Value)
-
-
-
-
12,053.00

About Synthetic Biologics

View Profile
Address
9605 Medical Center Drive
Rockville Maryland 20850
United States
Employees -
Website http://www.syntheticbiologics.com
Updated 07/08/2019
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation.